[1] Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease [J]. Neurology, 2004, 63 (6): 975-982.
[2] Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular abeta and synaptic dysfunction [J]. Neuron, 2003, 39 (3): 409- 421.
[3] Burns JM, Galvin JE, Roe CM, et al. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs [J]. Neurology, 2005, 64 (8): 1397-1403.
[4] Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer’s disease: allopregnanolone as a proof of concept neurogenic agent [J]. Curr Alzheimer Res, 2006, 3 (3): 185-190.
[5] Kawai H, Kotake Y, Ohta S, et al. Dopamine transporter and catechol-O-methyltransferase activities are required for the toxicity of
1-(3’,4’-dihydroxybenzyl)-1,2,3, 4-tetrahydroisoquinoline [J]. Chem Res Toxicol, 2000, 13 (12): 1294-1301.
[6] Wu LSh, Wang L, Ma YQ, et al. The innervations of rat pineal body: study by using immunohistochemical and morphometric methods [J]. Acta Anatomica Sinica, 2005, 36 (3): 288-291. (in Chinese)
吴亮生,王蕾,马玉琼,等. 大鼠松果体的神经支配—免疫组织化学及光镜体视学研究[J]. 解剖学报,2005, 36 (3): 288-291.
[7] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with the Pittsburgh compound-B [J]. Ann Neurol, 2004, 55 (3): 306-319.
[8] Jimenez-Escrig A, Rabano A, Guerrero C, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism [J]. Eur J Neurol, 2004, 11 (10): 663-669.
[9] Perez SE, Lazarov O, Koprich JB, et al. Nigrostriatal dysfunction in familial Alzheimer’s disease-linked APPswe/PS1DeltaE9 transgenic mice [J]. J Neurosci, 2005, 25 (44): 10220-10229.
[10] O’ Neil JN, Mouton PR, Tizabi Y, et al. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice [J]. J Chem Neuroanat, 2007, 34 (3-4): 102-107.
[11] German DC, Nelson O, Liang F, et al. The PDAPP mouse model of Alzheimer’s disease: locus coeruleus neuronal shrinkage [J]. J Comp Neurol, 2005, 492 (4): 469- 476.[12] Arias-Carrión O, Yamada E, Freundlieb N, et al. Neurogenesis in substantia nigra of parkinsonian brains [J]? J Neural Transm Suppl, 2009, (73): 279-285.
[13] Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic interactions between abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline [J]. J Neurosci, 2010, 30 (21): 7281-7289.
[14] Wang JM, Johnston PB, Ball BG, et al. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell cycle gene and protein expression [J]. J Neurosci, 2005, 25 (19): 4706-4718.
[15] Wang JM, Sun C. Calcium and neurogenesis in Alzheimer’s disease [J]. Front Neurosci, 2010, 4: 194.
[16] Brinton RD, Wang JM. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer’s disease [J]. Curr Alzheimer Res, 2006, 3 (1): 11-17.
[17] Bjugstad KB, Teng YD, Redmond DE Jr, et al. Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson’s disease [J]. Exp Neurol, 2008, 211 (2): 362-369. |